The aims of the present study were to explore whether a long-term intervention with dietary nitrate [(NO 3 À ), a potential tolerancefree source of beneficial vasoactive nitric oxide] and spironolactone (to oppose aldosterone's potential deleterious cardiovascular effects) improve cardiac structure/function, independently of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at risk of heart failure).
Introduction
Type 2 diabetes (T2DM) is a major risk factor for heart failure (HF) [1] , with either reduced (HFrEF) or preserved (HFpEF) ejection fraction [2] . Patients with T2DM are particularly susceptible to increased left ventricular (LV) volumes if they take drugs which cause fluid retention/increase preload, such as pioglitazone [3] . Conversely, simply lowering blood pressure (BP) with losartan or atenolol in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study did not alter LV volumes in patients with diabetes [4] .
Decreased production of nitric oxide (NO) [5, 6] , a key regulator of vascular homeostasis, by NO synthases and/or decreased bioavailability of NO [e.g. due to excess reactive oxygen species (ROS)], is implicated in vascular dysfunction in cardiovascular disease and T2DM [7] , LV diastolic dysfunction [8] , HF [9] and HFpEF [10] . However, standard approaches to supplementing NO using organic nitrates, such as isosorbide mononitrate, lack benefit [11] . This loss of effect with chronic ingestion may be due to nitrate tolerance via decreased bioactivation, increased ROS production and endothelial dysfunction [12] . An alternative therapeutic approach may be via dietary inorganic nitrate (NO 3 À ), as found in green leafy vegetables and beetroot [13] . Nitrate is reduced to nitrite (NO 2 À ) via the entero-salivary circulation, and further reduced to NO in a hypoxia-dependent process. This ʻnitrate-nitrite-NO pathwayʼ appears to lack these tolerance issues [14] , and to suppress ROS [15] and reverse endothelial dysfunction [16] , and has been extensively investigated clinically in studies up to 4-6 weeks, particularly for BP lowering [14, [16] [17] [18] [19] . By contrast, patients with T2DM appear to lack any effect of dietary nitrate on BP [19] [20] [21] . However, we recently reported (with the main haemodynamic findings of the current study) that dietary nitrate lowered central aortic systolic BP {SBP; mean À2.6 [95% confidence interval (CI) À4.5, À0.75] mm Hg; p = 0.007}, despite no effect on brachial BP [22] . This is consistent with our previous findings, whereby inorganic nitrite was found acutely and selectively to lower central aortic pressure through a normoxia-dependent dilatory effect on conduit arteries (radial) in healthy volunteers [23, 24] , and selectively to dilate epicardial coronary arteries in patients undergoing coronary angiography [25] .
Another important cause of HF in patients with T2DM is myocardial infarction due to coronary artery disease, with nitrite displaying a potential role in coronary ischaemiareperfusion injury (IRI) [26] , acute ST-elevation myocardial infarction (STEMI) [27, 28] and remote ischaemic preconditioning (RIPC) [29, 30] . Moreover, it was shown that chronic, 4-9 weeks' oral sodium nitrite supplementation prevented the increases in end-diastolic volume (EDV) and end-systolic volume (ESV) in murine models of IRI following left coronary artery occlusion [31] , and also prevented pressure overload-induced LV hypertrophy (LVH) with trans-aortic constriction [9] .
In contrast to NO supplementation, mineralocorticoid antagonists are established treatments in HF and hypertension, combatting aldosterone-mediated deleterious cardiovascular effects [32] , with 40 weeks' spironolactone [5, 33] improving LV mass (LVM), arterial stiffness [measured as pulse wave velocity (PWV)], augmentation index and aortic distensibility, in parallel with the reduction in BP, in patients with stage 2-3 chronic kidney disease [34] .
Given the potential for long-term dietary nitrate, and spironolactone, to improve cardiac structure or function, alongside, or independently of, any changes in arterial haemodynamics, we prospectively performed echocardiograms in a subsample of patients participating in our VaSera factorial randomized controlled trial (RCT) [22, 35] , with the a priori intention of exploring these specific mechanisms independently of BP, following chronic, 6 months' treatment with dietary nitrate ('Beet-it®' or 'Beet-it Sport®' beetroot juice), and/or spironolactone.
The primary hypothesis for the main study was that spironolactone, dietary nitrate or both could reduce arterial stiffness, measured by PWV, as a treatment target formally independent of BP. We recently reported that the primary outcome, change in arterial stiffness as cardio-ankle vascular index (CAVI), a nominally BP-independent measure, was no different between spironolactone and doxazosin [5, 36] (p = 0.08) [22] . In addition, and against the hypothesis, the secondary outcome, aortic PWV by arteriography adjusted for peripheral BP differences at baseline and BP change between trial arms from the trial's start to end, was lower with doxazosin than spironolactone (p = 0.045). Dietary nitrate had no effect on PWV.
Methods

Study population
A subsample of patients (with, or at risk of, T2DM) who were consented and randomized in our VaSera factorial RCT had serial transthoracic cardiac ultrasound performed during the course of the study. The study design and methods have previously been described in detail [35] . Briefly, participants with or at risk of T2DM were recruited from Guy's and St Thomas' Hospitals, London, UK, and surrounding areas between 2013 and 2015. Inclusion criteria were age 18-80 years, clinically diagnosed with, or at risk of, T2DM [as body mass index (BMI) ≥27 kg m -2 , positive family history or glucose intolerance after 75 g challenge] and ability to understand and comply with the protocol. Exclusion criteria included an interfering chronic illness, adverse reaction to either drug, known allergy to beetroot, estimated glomerular filtration rate <45 ml min -1 , glycated haemoglobin >11%
(97 mM M -1 ), or if participants were pregnant, breast feeding or had atrial fibrillation.
The results for the primary outcome (arterial stiffness) are described above and have been published separately [22] . The study was reviewed and approved by Central London National Research Ethics Service (NRES) and took place in the Clinical Research Facility (CRF) of St Thomas's Hospital. (Clinical trial registration: ISRCTN25003627/DOI 10.1186/ ISRCTN25003627). After initial consent and screening/ familiarization, visit 1 (V1), and having met the inclusion criteria, patients were invited to return for double randomization (in blocks of six) at visit 2 (V2), with simultaneous allocation to both types of intervention for each patient -therefore into one of four groups [35] ; see Figure 1 for study flow diagram. After cardiac and vascular measurements, treatments comprised either spironolactone 12.5 mg once daily for 1 week titrated to twice daily, OR doxazosin 2 mg once daily for 1 week titrated to twice daily, AND either nitrate-containing beetroot juice (BEET-IT®, nitrate 4.5 mmol day -1 ) or placebo beetroot juice. The juices were identical in appearance, smell and taste, with the nitrate having been removed from placebo juice by ion exchange (nitrate~0 mmol day -1 ). Following two check-up visits (V3 and V4; at 2 weeks and 8 weeks, respectively), cardiac and vascular measures were repeated at 3 months (V5). Then, provided that there were no contraindications, medication doses were increased (to spironolactone 25 mg twice daily or doxazosin 8 mg twice daily) and a more concentrated nitratecontaining beetroot juice was used (BEET-IT® Elite Sports Shot, 11.2 mmol nitrate day
, or matching placebo juice,~0 mmol nitrate day -1 ). The final visit (V6) was at 6 months postrandomization, when V2 and V5 cardiovascular assessments were repeated.
Thus, in this factorial design, approximately half the patients were randomized to active, nitrate-containing beetroot juice, and the other half to the placebo nitrate-depleted juice (with no difference in BP expected, based on the other studies of dietary nitrate in patients with T2DM described above). In addition, half the patients were randomized to spironolactone, and the other half to doxazosin as control Figure 1 Study flow diagram. At visit 2, the spironolactone dosage regimen was 12.5 mg once daily for 1 week, titrated to twice daily [indicated in the diagram as (1-2× day -1 )]; the doxazosin dosage regimen was 2 mg once daily for 1 week, titrated to twice daily [indicated in the diagram as (1-2×
. At visit 5, the doses of each were doubled, but frequencies maintained at twice daily (2× day -1 )]
(expected to produce similar changes in BP from baseline, but no difference between the treatments). The factorial design was intended to permit determination of the independent effects of nitrate vs. placebo, and spironolactone vs. doxazosin, following testing for drug-dietary nitrate interactions for BP and for echocardiographic parameters.
Echocardiography
Echocardiography was added to the protocol and offered to as many of the patients as possible, to explore mechanisms related to standard cardiac structure and function assessments, in parallel with the key haemodynamic outcome measures of the main study. Transthoracic cardiac ultrasound was performed using a GE Vivid 7 Ultrasound System. All measurements were performed by two expert operators, and all images analysed by a single operator blinded to the intervention. Acquisitions were individually optimized for depth, gain and frame rate, to [38] , as was the ratio E/E' for evaluating LV filling pressure.
Statistical considerations
Analyses were conducted by our independent biostatistician (S.M.), modified intent-to-treat, consisting of all randomized patients, except those with no outcome data at any followup visit. Patients with missing data at some visits were included, and we assumed that data were missing at random (i.e. unrelated to the unobserved value). We used mixedeffect models to estimate the effect of the interventions, and included gender, age, ethnicity (European, African-Caribbean, West African and other), a diagnosis of diabetes and the baseline value of the outcome as covariates. This was a prespecified/prospectively conducted, hypothesis-generating, exploratory mechanistic part of the main study. Thus, we present the least squares mean changes from baseline and differences between drugs and between juices, averaged over both follow-up visits for each outcome, with 95% CIs, rather than as hypothesis-testing P-values, in accordance with the recent editorial by Ring et al. [39] .
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [5] . 
Results
A total of 105 participants had echocardiograms at baseline (V2), of whom 87 (83%) also had follow-up data collected at V5 (3 months) and V6 (6 months) (see Figure 2) . Participant details and baseline echocardiographic parameters in each treatment arm are shown in Table 1 . The baseline LVMI (mean ± standard deviation) was 53 ± 13.5 g m -2.7 ; 52% met the criteria for LVH [37] , and 95%
had normal LV filling pressure (average E/A 1 ± 0.4, E/E' 7.8 ± 2.2).
Haemodynamic parameters
Spironolactone and doxazosin both reduced SBP by about 6 mmHg compared with baseline, with no difference between treatments (Table 2 ; Figure 3A ,B). Changes in diastolic BP (DBP) were also similar (~5 mmHg) with each drug ( Figure 3C ,D), with no change in heart rate (HR). There were no differences in brachial SBP, DBP or HR between nitrate-containing vs. nitrate-depleted juice ( Figure 4) . No drug-dietary nitrate interactions were detected for BP or for echocardiographic parameters; therefore, the effects of the drugs and dietary nitrate were estimated from models with no interaction term.
Echocardiographic morphological parameters
Compared with placebo juice (n = 47), nitrate-containing beetroot juice (n = 40) decreased EDV: À6.33 (À11.1, -1.57) ml and ESV: À3.2 (À5.9, -0.5) ml (see Table 2 and Figure 5 ). In addition, EDV and ESV decreased relative to baseline with nitrate-containing beetroot juice: À4.77 (À8.10, 1.44) ml and À 2.77 (À4.66, -0.89) ml, respectively, but not with placebo juice: À1.56 (À1.67, 4.80) ml and À0.40 (À1.43, 2.22) ml. The reduction in LVMI from baseline was similar between nitrate-containing and placebo juices, with no difference between interventions. Therefore, the ratio between LVM and LV volume -the M/V ratio -increased by 0.04 (0.00, 0.07) between active and nitrate-containing beetroot juices. Relative to baseline, LAVI fell with active juice: À1.59 (À2.64, -0.54) ml m ; however, there was no difference in LAVI between the interventions (active versus placebo juice): À1.33 (À2.83, 0.17) ml m . In contrast to nitrate, the only between-group difference in morphological parameters with spironolactone (n = 44) was a marginal reduction in relative wall thickness (RWT): À0.01 (À0.02, 0.00) vs. doxazosin (n = 43) (see Table 2 ). Spironolactone reduced LVMI relative to baseline: À1.48 (À2.08, À0.88) g m -2.7 , but there was no difference vs. 
Echocardiographic systolic-diastolic function
Among parameters of systolic-diastolic function, the E/A ratio fell with spironolactone from baseline: À0.07 (À0.12, -0.02), and vs. doxazosin: À0.12 (À0.19, -0.04) (see Figure 6A ,B). The tissue Doppler systolic function index, S 0 , increased with spironolactone vs. doxazosin, by 0.52 (0.05, 1.00) cm s -1 (see Figure 6C,D) .
The only change in systolic-diastolic function parameters observed with nitrate-containing beetroot juice was a prolongation of the deceleration time (DT) by 19.50 (8.40, 30 .60) ms and 19.74 (4.47, 36.01) ms relative to baseline and nitratedepleted juice, respectively.
Discussion
We found that 6 months' intervention with dietary nitrate in the form of beetroot juice may reduce LV volumes (EDV and ESV) compared with placebo (nitrate-depleted juice). The lack of any change in LVM by active juice suggests a favourable effect of nitrate on LV structure, and possibly on myocardial wall stress (as LV volumes were reduced, while BP was unaffected). In addition, spironolactone decreased RWT, suggesting a beneficial effect on myocardial remodelling, and improved parameters of systolic-diastolic function [systolic function index (S 0 ), E/A] compared with doxazosin.
These effects were also independent of BP (which was no different between spironolactone and doxazosin). The chronic effect of nitrate on reducing LV volumes has important implications for HFpEF, and builds on the beneficial acute actions of nitrate/nitrite recently demonstrated on exercise performance and left heart filling pressures [pulmonary capillary wedge pressure (PCWP)], in patients with HFpEF [40] [41] [42] [43] . Indeed, across two randomized, doubleblind, placebo-controlled studies by Borlaug and colleagues, one in 28 patients [41] and the other in a subset of 52 of 98 patients with HFpEF [43] , in both cases with patients undergoing invasive haemodynamic exercise testing, sodium nitrite (either intravenous or nebulized-inhaled) acutely decreased aortic wave reflections (at rest), and improved arterial compliance, elastance and central haemodynamics (during exercise), and left heart filling pressures (PCWP), compared with placebo [41, 43] . However, no clinical data are available on the long-term effects of dietary nitrate on cardiac structure and function. This is a key question, given the problems of tolerance associated with organic nitrates. Therefore, the current study provides the most extensive evidence to date of the long-term cardiac effects of dietary nitrate and has biological plausibility, building on the translational study of 9 weeks' supplementation with oral nitrite which showed decreased EDV and ESV vs. placebo in the mouse model of pressure overload-induced LVH with transaortic constriction [9] . Regarding the specific changes in ventricular volumes in our study, it can be speculated that dietary nitrate-derived nitrite is likely to act on ventricular preload by influencing venous dilatation [24, 44] and pressure, although, as nitrate salts are also known to have diuretic activity, this could play a role. No direct measures of preload were collected here; however, changes in indirect parameters, such as ventricular volumes, as demonstrated with intravenous organic nitrate therapy [45] , support this. Indeed, previous invasive studies have used EDV to define LV preload [46, 47] . Moreover, the reduction in LV volumes, but not LVMI, resulted in an increased M/V ratio. This suggests a positive action on cardiac remodelling [48] and myocardial wall stress [49] , with potential favourable prognostic implications [50] .
In contrast to nitrate, ventricular volumes were not altered by spironolactone, which instead improved other structural and functional cardiac parameters. Spironolactone has previously been demonstrated to improve cardiac hypertrophy and remodelling in hypertensive patients [51] , although this was not shown in patients with T2DM [52] . In our population, there was some evidence that spironolactone decreased RWT and LVMI, suggesting a direct action of spironolactone on cardiac remodelling (that was independent of BP). If confirmed, this finding would be relevant because cardiac remodelling is a prognostic factor for cardiovascular events -even in the absence of LVH [53] .
Our results also suggest important differential actions of the two drugs on cardiac performance (S 0 and E/A). S 0 is considered to be a sensitive TDI index of systolic function [54] , and this was increased by spironolactone compared with doxazosin.
Spironolactone has previously been found to have beneficial effects on diastolic function [55, 56] . In subclinical diabetic cardiomyopathy, spironolactone decreased conventional Doppler parameters (E/A), without affecting E/E' [51] , despite evidence of elevated LV diastolic filling pressure (E/E' 14.3 ± 7). We also observed a reduction in E/A ratio with spironolactone, with no change in E/E', which was within the normal range at baseline. Therefore, the reduction in E/A may reflect an improvement in diastolic function that is not limited to alterations in preload, as other parameters sensitive to preload, such as EDV, ESV and LAVI (as well as BP and HR), were not affected by spironolactone (Table 2) . However, diastolic function is a complex phenomenon and a ʻsingle parameterʼ approach does not provide a comprehensive overview [38] .
Overall, these results indicate that dietary nitrate may have BP-independent beneficial actions on myocardial remodelling over and above the established effects of spironolactone. This could be explained by different mechanisms of action -mainly cardiac preload for dietary nitrate vs. a direct antiremodelling effect for spironolactone -although a direct action of nitrate/nitrite on the myocardium cannot be excluded and should be further investigated.
We acknowledge several limitations of our study: cardiac analysis was not the primary outcome of the VaSera trial and our analyses were therefore exploratory; the overall Chronic cardiac effects of dietary nitrate sample size was relatively small (87 patients with follow-up data), so confidence intervals were wide; follow-up data were incomplete, and the mixed-effects model may not adequately account for any bias this could have introduced.
Conclusion
Six months' dietary nitrate decreased LV volumes by~5%, representing sustained, BP-independent effects on cardiac structure, suggesting a beneficial action on cardiac remodelling, with potential consequences on cardiovascular disease prevention/treatment. Spironolactone independently decreased LV wall thickness and modified parameters of systolic-diastolic function.
